المؤلفون: RODRIGUEZ-RIVERA, CARMEN, Monreal, Enric, Montpeyó Garcia-Moreno, Marta, Urcelay, Elena, Perez-Garcia, Maria J, Miguez, Andrés, Malhotra Sareen, Sunny, Fissolo, Nicolás Miguel, Segura, Miguel F., Pappolla, Agustin, Rio, Jordi, Vilaseca Jolonch, Andreu, Martinez-Vicente, Marta, Montalban, Xavier, Comabella Lopez, Manuel

المساهمون: Institut Català de la Salut, Malhotra S, Fissolo N, Pappolla A, Río J, Vilaseca A, Miguez A, Montalban X, Comabella M Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Rodríguez-Rivera C Area of Pharmacology and Nutrition & Bromatology, Department of Basic Health Sciences, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain. Monreal E Department of Neurology, Hospital Universitario Ramón y Cajal, REEM, IRYCIS, Universidad de Alcalá, Madrid, Spain. Montpeyo M, Martinez-Vicente M Grup de Recerca de Malalties Neurodegeneratives, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain. Urcelay E Laboratorio de Investigación en Genética de Enfermedades Complejas, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. Pérez-García MJ, Segura MF Grup de Recerca de Càncer i Malalties Hematològiques Infantils, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Marcadors bioquímics, Esclerosi múltiple - Tractament, Medicaments immunosupressors - Efectes secundaris, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents, Other subheadings::Other subheadings::Other subheadings::/adverse effects, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis, Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Biological Factors::Biomarkers, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios::inmunosupresores, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores

الوصف: Clusterin deficiency; Teriflunomide; Multiple sclerosis ; Deficiència de clusterina; Teriflunomida; Esclerosi múltiple ; Deficiencia de clusterina; Teriflunomida; Esclerosis múltiple ; This research was conducted using Departmental funds for Medical Research.

وصف الملف: application/pdf

العلاقة: Clinical and Translational Medicine;14(4); https://doi.org/10.1002/ctm2.1654Test; Malhotra S, Fissolo N, Rodríguez-Rivera C, Monreal E, Montpeyo M, Urcelay E, et al. Clusterin deficiency is associated with a lack of response to teriflunomide in multiple sclerosis. Clin Transl Med. 2024 Apr;14(4):e1654.; https://hdl.handle.net/11351/11332Test; 001198705100001

الإتاحة: https://doi.org/10.1002/ctm2.1654Test
https://hdl.handle.net/11351/11332Test

المؤلفون: Carbonell Mirabent, Pere, Rodríguez Barranco, Marta, Castillo Justribo, Joaquin, Guío-Sánchez, Claudia, Carvajal, René, Zabalza, Ana, Martínez-Gómez, Xavier, Esperalba, Juliana, Pappolla, Agustin, Rando Segura, Ariadna, Cobo-Calvo, Alvaro, TUR, CARMEN, Rio, Jordi, Comabella Lopez, Manuel, Rodrigo Pendás, José Ángel, Braga da Silva Rezende, Nathane, Mongay-Ochoa, Neus, Vidal-Jordana, Angela, Arrambide, Georgina, Rodriguez Acevedo, Breogan, midaglia, luciana, BORRAS BERMEJO, BLANCA, Sastre Garriga, Jaume, Montalban, Xavier, Otero-Romero, Susana, Tintore, Mar, Galan, Ingrid

المساهمون: Institut Català de la Salut, Carvajal R, Zabalza A, Carbonell-Mirabent P, Pappolla A, Cobo-Calvo A, Tur C, Rodriguez M, Río J, Comabella M, Castilló J, Braga N, Mongay-Ochoa N, Guío-Sánchez C, Vidal-Jordana Á, Arrambide G, Rodríguez-Acevedo B, Midaglia L, Galán I, Sastre-Garriga J, Montalban X Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Martínez-Gómez X, Rodrigo-Pendás JÁ, Borras-Bermejo B Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Esperalba J Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Rando A Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Montalban X, Tintoré M Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Vic, Spain. Otero-Romero S Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain., Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Anticossos monoclonals - Ús terapèutic, Esclerosi múltiple - Tractament, Vacunes, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal, PHENOMENA AND PROCESSES::Immune System Phenomena::Antibody Formation::Immunogenicity, Vaccine, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis, Other subheadings::Other subheadings::Other subheadings::/drug therapy, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales, FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::formación de anticuerpos::inmunogenicidad vacunal, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia

الوصف: Immunogenicity; Vaccine; Multiple sclerosis ; Immunogenicitat; Vacuna; Esclerosi múltiple ; Inmunogenicidad; Vacuna; Esclerosis múltiple ; Importance Vaccination in patients with highly active multiple sclerosis (MS) requiring prompt treatment initiation may result in impaired vaccine responses and/or treatment delay. Objective To assess the immunogenicity and safety of inactivated vaccines administered during natalizumab treatment. Design, Setting, and Participants This self-controlled, prospective cohort study followed adult patients with MS from 1 study center in Spain from September 2016 to February 2022. Eligible participants included adults with MS who completed immunization for hepatitis B virus (HBV), hepatitis A virus (HAV), and COVID-19 during natalizumab therapy. Data analysis was conducted from November 2022 to February 2023. Exposures Patients were categorized according to their time receiving natalizumab treatment at the time of vaccine administration as short-term (≤1 year) or long-term (>1 year). Main Outcomes and Measures Demographic, clinical, and radiological characteristics were collected during the year before vaccination (prevaccination period) and the year after vaccination (postvaccination period). Seroprotection rates and postvaccination immunoglobulin G titers were determined for each vaccine within both periods. Additionally, differences in annualized relapse rate (ARR), new T2 lesions (NT2L), Expanded Disability Status Scale (EDSS) scores, and John Cunningham virus (JCV) serostatus between the 2 periods were assessed. Results Sixty patients with MS (mean [SD] age, 43.2 [9.4] years; 44 female [73.3%]; 16 male [26.7%]; mean [SD] disease duration, 17.0 [8.7] years) completed HBV, HAV, and mRNA COVID-19 immunization during natalizumab treatment, with 12 patients in the short-term group and 48 patients in the long-term group. The global seroprotection rate was 93% (95% CI, 86%-98%), with individual vaccine rates of 92% for HAV (95% CI, 73%-99%), 93% for HBV (95% CI, 76%-99%), and 100% ...

وصف الملف: application/pdf

العلاقة: JAMA Network Open;7(4); https://doi.org/10.1001/jamanetworkopen.2024.6345Test; info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01606; Carvajal R, Zabalza A, Carbonell-Mirabent P, Martínez-Gómez X, Esperalba J, Pappolla A, et al. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab. JAMA Netw Open. 2024 Apr 1;7(4):e246345–e246345.; https://hdl.handle.net/11351/11344Test

الإتاحة: https://doi.org/10.1001/jamanetworkopen.2024.6345Test
https://hdl.handle.net/11351/11344Test

المؤلفون: Arnold, Douglas, Elliott, Colm, Martin, Emily C., Hyvert, Yann, Tomic, Davorka Lucia, Montalban, Xavier

المساهمون: Institut Català de la Salut, Arnold DL Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada. NeuroRx Research, Montreal, Quebec, Canada. Elliott C NeuroRx Research, Montreal, Quebec, Canada. Martin EC EMD Serono, Billerica, MA. Hyvert Y The Healthcare Business of Merck KGaA, Darmstadt, Germany. Tomic D Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Montalban X Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Proteïnes quinases - Inhibidors - Ús terapèutic, Esclerosi múltiple - Tractament, CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases, Other subheadings::Other subheadings::Other subheadings::/antagonists & inhibitors, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Relapsing-Remitting, COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-tirosina cinasas, Otros calificadores::Otros calificadores::Otros calificadores::/antagonistas & inhibidores, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple recurrente-remitente

الوصف: Evobrutinib; Lesion; Relapsing multiple sclerosis ; Evobrutini; Lesión; Esclerosis múltiple recurrente ; Evobrutinib; Lesió; Esclerosi múltiple recurrent ; Background and Objectives Chronic active lesions (CALs) are demyelinated multiple sclerosis (MS) lesions with ongoing microglia/macrophage activity, resulting in irreversible neuronal damage and axonal loss. Evobrutinib is a highly selective, covalent, CNS-penetrant, Bruton tyrosine kinase inhibitor. This post hoc analysis evaluated the effect of evobrutinib on slowly expanding lesion (SEL) volume, an MRI marker of CALs, assessed baseline–week 48 in a phase 2, double-blind, randomized trial (NCT02975349) in relapsing MS (RMS). Methods In the 48-week, double-blind trial, adult patients received evobrutinib (25 mg once daily [QD], 75 mg QD, or 75 mg twice daily [BID]), placebo (switched to evobrutinib 25 mg QD after week 24), or open-label dimethyl fumarate (DMF) 240 mg BID. SELs were defined as slowly and consistently radially expanding areas of preexisting T2 lesions of ≥10 contiguous voxels (∼30 mm3) over time. SELs were identified by MRI and assessed by the Jacobian determinant of the nonlinear deformation from baseline to week 48. SEL volume analysis, stratified by baseline T2 lesion volume tertiles, was based on week 48/end-of-treatment status (completers/non-completers). Treatment effect was analyzed using the stratified Hodges-Lehmann estimate of shift in distribution and stratified Wilcoxon rank-sum test. Comparisons of evobrutinib and DMF vs placebo/evobrutinib 25 mg QD were made. Subgroup analyses used pooled treatment groups (evobrutinib high dose [75 mg QD/BID] vs low dose [placebo/evobrutinib 25 mg QD]). Results The SEL analysis set included 223 patients (mean [SD] age: 42.4 [10.7] years; 69.3% female; 87.4% relapsing/remitting MS). Mean (SD) SEL volume was 2,099 (2,981.0) mm3 with evobrutinib 75 mg BID vs 2,681 (3,624.2) mm3 with placebo/evobrutinib 25 mg QD. Median number of SELs/patient ranged from 7 to 11 across treatments. SEL volume ...

وصف الملف: application/pdf

العلاقة: Neurology;102(5); https://doi.org/10.1212/WNL.0000000000208058Test; Arnold DL, Elliott C, Martin EC, Hyvert Y, Tomic D, Montalban X. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis. Neurology. 2024 Mar 12;102(5):e208058.; https://hdl.handle.net/11351/11085Test

الإتاحة: https://doi.org/10.1212/WNL.0000000000208058Test
https://hdl.handle.net/11351/11085Test

المؤلفون: Kappos, Ludwig, Li, David K B, Bar-Or, Amit, Barkhof, Frederik, Traboulsee, Anthony, Montalban, Xavier

المساهمون: Institut Català de la Salut, Kappos L Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel, Basel, Switzerland. Traboulsee A Department of Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada. Li DKB Department of Radiology and Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada. Bar Or A Center for Neuroinfammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Barkhof F VU University Medical Centre, Amsterdam, The Netherlands. UCL Institutes of Biomedical Engineering and Neurology, London, UK. Montalban X Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Avaluació de resultats (Assistència sanitària), Esclerosi múltiple - Tractament, Anticossos monoclonals - Ús terapèutic, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Relapsing-Remitting, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple recurrente-remitente, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento

الوصف: Disease-modifying therapies; Multiple sclerosis; Ocrelizumab ; Terapias modificadoras de la enfermedad; Esclerosis múltiple; Ocrelizumab ; Teràpies modificadores de la malaltia; Esclerosi múltiple; Ocrelizumab ; Open-label extension (OLE) studies help inform long-term safety and efficacy of disease-modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase 2 trial on the longest follow-up to date of ocrelizumab-treated patients with relapsing–remitting MS (RRMS). The primary treatment period (PTP) comprised four 24-week treatment cycles; participants were randomized to double-blind ocrelizumab (2000 mg or 600 mg), placebo, or interferon β-1a (open label) for one cycle, then dose-blinded ocrelizumab 1000 mg or 600 mg for the remaining cycles. The PTP was followed by consecutive assessed and unassessed treatment-free periods (TFPs) and then the OLE (ocrelizumab 600 mg every 24 weeks). Safety and efficacy were prospectively assessed. Of 220 participants randomized, 183 (84%) completed the PTP. After the TFP, 103 entered OLE (median OLE ocrelizumab exposure 6.5 years). Most common adverse events across all periods were infusion-related reactions. MRI activity, annualized relapse rate, and confirmed disability progression (CDP) rates remained low throughout. During the assessed TFP, there was a trend toward less and later B-cell repletion, and later CDP, for patients randomized to ocrelizumab; MRI activity was observed in 16.3% of patients, the earliest 24 weeks after the last ocrelizumab dose. This is the longest follow-up of ocrelizumab-treated patients with RRMS, with no new safety signals emerging during an observation period from 2008 to 2020. Results reinforce the sustained efficacy of long-term ocrelizumab. Reduced disease activity was maintained following interruption of 6-month dosing cycles, with no evidence of rebound. ; This research was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Editorial assistance for this article was provided by Nicholas Fitch and Martha ...

وصف الملف: application/pdf

العلاقة: Journal of Neurology;271; https://doi.org/10.1007/s00415-023-11943-4Test; Kappos L, Traboulsee A, Li DKB, Bar-Or A, Barkhof F, Montalban X, et al. Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. J Neurol. 2024 Feb;271:642–57.; https://hdl.handle.net/11351/10957Test; 001096151600002

الإتاحة: https://doi.org/10.1007/s00415-023-11943-4Test
https://hdl.handle.net/11351/10957Test

المؤلفون: Miro, Berta, Fissolo, Nicolás Miguel, Castillo Justribo, Joaquin, midaglia, luciana, Rovira, Alex, Rio, Jordi, Sánchez-Pla, Alex, Montalban, Xavier, Comabella Lopez, Manuel

المساهمون: Institut Català de la Salut, Midaglia L, Río J, Fissolo N, Castilló J, Montalban X, Comabella M Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Rovira A Secció de Neurorradiologia, Radiodiagnòstic (IDI), Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Miró B, Sánchez A Unitat d’Estadística i Bioinformàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Esclerosi múltiple - Tractament, Imatgeria per ressonància magnètica, Marcadors bioquímics, Fenotip, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Relapsing-Remitting, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging, PHENOMENA AND PROCESSES::Genetic Phenomena::Phenotype, CHEMICALS AND DRUGS::Biological Factors::Biomarkers, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple recurrente-remitente, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética, FENÓMENOS Y PROCESOS::fenómenos genéticos::fenotipo, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores

الوصف: Magnetic resonance imaging; Multiple sclerosis; Neurofilament light chain ; Imagen de resonancia magnética; Esclerosis múltiple; Cadena ligera de neurofilamento ; Imatges per ressonància magnètica; Esclerosi múltiple; Cadena lleugera de neurofilament ; Background and purpose The aim was to evaluate whether magnetic resonance imaging (MRI) phenotypes defined by inflammation and neurodegeneration markers correlate with serum levels of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in relapsing–remitting multiple sclerosis (RRMS) patients; and to explore the role of radiological phenotypes and biomarker levels on treatment response and long-term prognostic outcomes. Methods Magnetic resonance imaging scans from 80 RRMS patients were classified at baseline of interferon-beta (IFNβ) treatment into radiological phenotypes defined by high and low inflammation and high and low neurodegeneration, based on the number of contrast-enhancing lesions, brain parenchymal fraction and the relative volume of non-enhancing black holes on T1-weighted images. Serum levels of NfL and GFAP were measured at baseline with single molecule array (Simoa) assays. MRI phenotypes and serum biomarker levels were investigated for their association with IFNβ response, and times to second-line therapies, secondary-progressive MS (SPMS) conversion and Expanded Disability Status Scale (EDSS) 6.0. Results Mean (SD) follow-up was 17 (2.9) years. Serum NfL levels and GFAP were higher in the high inflammation (p = 0.04) and high neurodegeneration phenotypes (p = 0.03), respectively. The high inflammation phenotype was associated with poor response to IFNβ treatment (p = 0.04) and with shorter time to second-line therapies (p = 0.04). In contrast, the high neurodegeneration phenotype was associated with shorter time to SPMS (p = 0.006) and a trend towards shorter time to EDSS 6.0 (p = 0.09). High serum NfL levels were associated with poor response to IFNβ treatment (p = 0.004). Conclusions Magnetic resonance imaging ...

وصف الملف: application/pdf

العلاقة: European Journal of Neurology;31(1); https://doi.org/10.1111/ene.16077Test; Midaglia L, Rovira A, Miró B, Río J, Fissolo N, Castilló J, et al. Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients. Eur J Neurol. 2024 Jan;31(1):e16077.; https://hdl.handle.net/11351/10961Test; 001072474700001

الإتاحة: https://doi.org/10.1111/ene.16077Test
https://hdl.handle.net/11351/10961Test

المؤلفون: Brochet, Bruno, Solari, Alessandra, Lechner-Scott, Jeannette, Piehl, Fredrik, langdon, dawn, Hupperts, Raymond, Montalban, Xavier

المساهمون: Institut Català de la Salut, Brochet B INSERM U 1215, University of Bordeaux, Bordeaux, France. Alessandra Solari Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. Jeannette Lechner-Scott University of Newcastle, Newcastle, NSW, Australia/ Division of Neurology, John Hunter Hospital, Newcastle, NSW, Australia. Fredrik Piehl Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Dawn Langdon Department of Psychology, Royal Holloway, University of London, Egham, UK. Raymond Hupperts Zuyderland Medisch Centrum Sittard, Maastricht University Medical Center, Maastricht, The Netherlands. Xavier Montalban Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Esclerosi múltiple - Tractament, Qualitat de vida, Medicaments antineoplàstics - Ús terapèutic, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis, Other subheadings::Other subheadings::Other subheadings::/drug therapy, PUBLIC HEALTH::Environmental Health::Science::Environmental Quality::Quality of Life, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents, Other subheadings::Other subheadings::/therapeutic use, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, SALUD PÚBLICA::salud ambiental::ciencia::calidad ambiental::calidad de vida, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos, Otros calificadores::Otros calificadores::/uso terapéutico

الوصف: Cladribine tablets; Multiple sclerosis; Quality of life ; Pastilles de cladribina; Esclerosi múltiple; Qualitat de vida ; Pastillas de cladribina; Esclerosis múltiple; Calidad de vida ; Background: Multiple sclerosis (MS) negatively affects health-related quality of life (HRQoL). Objective: To evaluate HRQoL in people with highly active relapsing MS treated with cladribine tablets (CladT; 3.5 mg/kg cumulative dose over 2 years) in CLARIFY-MS. Methods: Changes in the MS quality of life (MSQoL)-54 scores were analysed using a repeated mixed-effects linear model. Subgroup analyses were performed for participants who were pretreatment-naïve and those pretreated with disease-modifying therapies (DMTs) before initiating CladT. Safety and tolerability of CladT were also assessed. Results: MSQoL-54 physical (mean change = 4.86; 95% confidence interval (CI) = 3.18, 6.53) and mental health (4.80; 95% CI = 3.13, 6.46) composite scores (primary endpoints) showed significant improvement at Month 24 versus Baseline (p < 0.0001). Changes in the MSQoL-54 scores were consistent across the pretreatment-naïve and DMT-pretreated subgroups. No new severe or opportunistic infections occurred. Most post-baseline lymphopenia events were Grade 1–2 in severity. Transient Grade-3 lymphopenia was observed in 19.7% (95/482) of participants. Grade-4 lymphopenia was not observed. Conclusions: CladT treatment significantly improved the mean MSQoL-54 physical and mental health composite scores over 2 years. CladT efficacy in HRQoL, relapse rates and Expanded Disability Status Scale scores demonstrates its multidimensional effects in MS treatment. ; This work was supported by Merck (CrossRef Funder ID: 10.13039/100009945).

وصف الملف: application/pdf

العلاقة: Multiple Sclerosis Journal;29(14); https://doi.org/10.1177/13524585231205962Test; Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, et al. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. Mult Scler. 2023 Dec;29(14):1808–18.; https://hdl.handle.net/11351/10810Test; 001106665100001

الإتاحة: https://doi.org/10.1177/13524585231205962Test
https://hdl.handle.net/11351/10810Test

المؤلفون: Boyko, Alexey, Correale, Jorge, Edan, Gilles, Freedman, Mark S, Giovannoni, Gavin, Montalban, Xavier

المساهمون: Institut Català de la Salut, Giovannoni G Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. Boyko A Pirogov Russian National Research Medical University, Department of Neurology, Neurosurgery and Medical Genetics, Federal Center of Brain Research and Neurotechnologies, Moscow, Russia. Correale J Department of Neurology, FLENI Institute, Buenos Aires, Argentina. Edan G Department of Neurology, University Hospital of Rennes, Rennes, France. Freedman MS University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada. Montalban X Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Esclerosi múltiple - Tractament, Medicaments immunosupressors - Ús terapèutic, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios::inmunosupresores

الوصف: Cladribina; Multiple sclerosis; Relapses ; Cladribina; Esclerosi múltiple; Recaigudes ; Cladribina; Esclerosis múltiple; Recaídas ; What is this summary about? Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies. What were the results? Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS. What do the results mean? The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment.

وصف الملف: application/pdf

العلاقة: Neurodegenerative Disease Management;13(5); https://doi.org/10.2217/nmt-2023-0018Test; Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, et al. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 Oct;13(5):261–8.; https://hdl.handle.net/11351/10717Test; 001042183200001

الإتاحة: https://doi.org/10.2217/nmt-2023-0018Test
https://hdl.handle.net/11351/10717Test

المؤلفون: Carvajal, René, Bollo, Luca, Rodríguez Barranco, Marta, Cobo-Calvo, Alvaro, Carbonell Mirabent, Pere, Rio, Jordi, Castillo Justribo, Joaquin, Braga da Silva Rezende, Nathane, Mongay-Ochoa, Neus, Arrambide, Georgina, Rodriguez Acevedo, Breogan, Zabalza, Ana, TUR, CARMEN, Martínez-Gómez, Xavier, Esperalba, Juliana, Pappolla, Agustin, BORRAS BERMEJO, BLANCA, Rodrigo Pendás, José Ángel, Vidal-Jordana, Angela, midaglia, luciana, Comabella Lopez, Manuel, Sastre Garriga, Jaume, Montalban, Xavier, Tintore, Mar, Otero-Romero, Susana, Galan, Ingrid

المساهمون: Institut Català de la Salut, Carvajal R, Tur C, Bollo L, Rodriguez M, Pappolla A, Cobo-Calvo A, Carbonell P, Río J, Castilló J, Braga N, Mongay-Ochoa N, Vidal-Jordana Á, Arrambide G, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Galán I, Comabella M, Sastre-Garriga J Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Martínez-Gómez X, Borras-Bemejo B, Rodrigo-Pendás JÁ Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Esperalba J Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Montalban X, Tintoré M Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Barcelona, Spain. Otero-Romero S Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Esclerosi múltiple - Tractament, Vacunació, Immunoglobulines, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunization::Immunotherapy, Active::Vaccination, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Viral, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunización::inmunoterapia activa::vacunación, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos víricos

الوصف: Multiple sclerosis; Infections; Vaccination ; Esclerosi múltiple; Infeccions; Vacunació ; Esclerosis múltiple; Infecciones; Vacunación ; Background: Mumps-Measles-Rubella (MMR) and Varicella zoster vaccines (VAR) are live attenuated vaccines, usually administered in a two-dose scheme at least 4 weeks apart. However, single-dose immunization schemes may also be effective and can reduce delays in immunosuppressive treatment initiation in patients with multiple sclerosis (pwMS) who need to be immunized. Objectives: To evaluate the immunogenicity of a single-dose attempt (SDA) versus the standard immunization scheme (SIS) with VAR and/or MMR in pwMS. Methods: Retrospective observational study in pwMS vaccinated against VAR and/or MMR. We compared seroprotection rates and antibody geometric mean titers (GMTs) between the two strategies. Results: Ninety-six patients were included. Thirty-one patients received VAR and 67 MMR. In the SDA group, the seroprotection rate was 66.7% (95% confidence interval (CI): 53.3–78.3) versus 97.2% (95% CI: 85.5–99.9) in the SIS (p < 0.001). For the seroprotected patients, GMTs were similar for both schemes. Conclusion: An SDA of VAR and/or MMR vaccines could be sufficient to protect almost two-thirds of patients. Testing immunogenicity after a single dose of VZ and/or MMR could be included in routine clinical practice to achieve rapid immunization. ; This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/01606 and co-funded by the European Union and ECTRIMS clinical fellowship awarded to René Carvajal from 2021 to 2022.

وصف الملف: application/pdf

العلاقة: Multiple Sclerosis Journal;29(14); https://doi.org/10.1177/13524585231200303Test; info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01606; Carvajal R, Tur C, Martínez-Gómez X, Bollo L, Esperalba J, Rodriguez M, et al. A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients. Mult Scler. 2023 Dec;29(14):1841–8.; https://hdl.handle.net/11351/10720Test; 001069475500001

الإتاحة: https://doi.org/10.1177/13524585231200303Test
https://hdl.handle.net/11351/10720Test

المؤلفون: Sancho-López, Arantxa, Ruiz-Antorán, Belén, Iglesias Hernangómez, Teresa, Ramírez-García, Almudena, Gómez-Estévez, Irene, Sanabria, Judith, Bosch Ferrer, Montserrat

المساهمون: Institut Català de la Salut, Sancho-López A, Ruiz-Antorán B, Ramírez-García A Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Spain. Iglesias Hernangómez T Clinical Pharmacology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain. Gómez-Estévez I Department of Neurology, Hospital Clinico San Carlos, IdISSC, Madrid, Spain. Department of Medicine, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain. Sanabria-Cabrera J Clinical Pharmacology Department, Hospital Universitario Virgen de la Victoria, IBIMA_Plataforma BIONAND, Universidad de Málaga, Malaga, Spain. Platform for Clinical Research and Clinical Trials IBIMA, Plataforma ISCIII de Investigación Clínica, Madrid, Spain. Bosch Ferrer M Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Farmacologia Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Farmacovigilància, Esclerosi múltiple - Tractament, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Evaluation Studies as Topic::Product Surveillance, Postmarketing::Pharmacovigilance, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::estudios de evaluación como asunto::vigilancia de productos comercializados::farmacovigilancia

الوصف: Lymphopenia; Multiple sclerosis; Pharmacovigilance ; Linfopenia; Esclerosis múltiple; Farmacovigilancia ; Limfopènia; Esclerosi múltiple; Farmacovigilància ; Background: Severe cases of lymphopenia have been reported during siponimod clinical trials, which may negatively impact its benefit/risk profile. Objective: We aimed to evaluate the incidence of lymphopenia following the initiation of siponimod treatment in clinical practice. The secondary objectives included the analysis of factors predisposing to and the clinical relevance of lymphopenia events. Methods: In this multicenter retrospective cohort study, information collected from the medical records of 129 patients with MS from 15 tertiary hospitals in Spain who initiated treatment with Siponimod were followed-up for at least 3 months, including at least one lymphocyte count evaluation per patient. Results: Of the 129 patients, 121 (93.6%) reported lymphopenia events, including 110 (85.3%) with grade ≤ 3 and 11 (8.5%) with grade 4 lymphopenia, higher than those reported in the pivotal clinical trial (73.3% and 3.3% for grade ≤ 3 and grade 4 lymphopenia, respectively). The study included an unexpectedly high proportion of male subjects (72.9%), which might have led to an underestimation of the actual magnitude of the risk. Conclusions: In this study, the incidence and severity of lymphopenia after starting siponimod treatment were higher than those reported in previous clinical trials. Therefore, our results reinforce the need for the closer monitoring of novel MS drugs in clinical practice, as well as larger and longer follow-up studies to properly characterize this risk.

وصف الملف: application/pdf

العلاقة: Journal of Clinical Medicine;12(20); https://doi.org/10.3390/jcm12206471Test; Sancho-López A, Ruiz-Antorán B, Iglesias Hernangómez T, Ramírez-García A, Gómez-Estévez I, Sanabria-Cabrera J, et al. The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study). J Clin Med. 2023 Oct 11;12(20):6471.; https://hdl.handle.net/11351/10590Test

الإتاحة: https://doi.org/10.3390/jcm12206471Test
https://hdl.handle.net/11351/10590Test

المؤلفون: Moharra, Montse, Hernández-Leal, María José, Robles-Sánchez, Miguel Ángel, Bosch, Cristina, Montalban, Xavier, Sastre Garriga, Jaume

المساهمون: Institut Català de la Salut, Robles-Sanchez MA Centre d'Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca Multidisciplinari d'Infermeria, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Faculty of Nursing, University of Girona, Girona, Spain. Moharra M Agency for Health Quality and Assessment of Catalonia (AQuAS), Department of Health of Catalonia, Barcelona, Spain. Bosch-Farré C Faculty of Nursing, University of Girona, Girona, Spain. Hernández-Leal MJ Department of Community, Maternity and Pediatric Nursing, School of Nursing, University of Navarra, Pamplona, Spain. Program in Medical Sciences, University of La Frontera, Temuco, Chile. Millennium Nucleus on Sociomedicine (SocioMed), Santiago, Chile. Montalban X Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Sastre-Garriga J Centre d'Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Decisió, Presa de, Esclerosi múltiple - Tractament, Pacients - Participació, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis, Other subheadings::Other subheadings::/therapy, HEALTH CARE::Health Care Facilities, Manpower, and Services::Health Services::Community Health Services::Community Participation::Patient Participation, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Clinical Decision-Making, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple, Otros calificadores::Otros calificadores::/terapia, ATENCIÓN DE SALUD::instalaciones, servicios y personal de asistencia sanitaria::servicios de salud::Servicios de Salud Comunitaria::participación de la comunidad::participación del paciente, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::toma de decisiones clínicas

الوصف: Multiple Sclerosis ; Esclerosi múltiple ; Esclerosis múltiple ; BACKGROUND: Patients with multiple sclerosis (MS) may experience decisional conflict during treatment choice. Shared decision making (SDM), whereby patients and health professionals, primarily nurses, collaborate in making decisions, reduces this decisional conflict. It requires understanding large amounts of information and may be complex, especially when decisions affect patients' autonomy and quality and prolongation of life. Patient decision aids are tools in facilitating SDM. This study aimed to identify the key elements from the perspective of patients with relapsing-remitting MS to create a patient decision aid in the Spanish sociocultural context. METHODS: This is a qualitative study using focus groups led by a clinical nurse specialist. Semistructured interviews included healthcare needs and demands, the SDM process, and general characteristics of a peer support program. After the transcription of interview recordings, data were analyzed by thematic analysis and a constructivist naturalistic approach. RESULTS: Patients with MS (27) from Spain participated in 4 focus groups of 90 to 120 minutes each. Three overarching themes were identified: information access to sufficient high-quality data; knowledge of available treatment options, including efficacy, adverse effects, frequency, administration route, and the impact on daily life; decision-making role, engaged versus nonengaged patients. The former require support in facilitating their active involvement in decisions, whereas the latter prefer more passive health models. CONCLUSION: The needs identified by patients with relapsing-remitting MS regarding treatment choice in the Spanish setting align with those reported by other studies. The identified themes provide valuable information to design and develop a virtual patient decision aid jointly by clinical MS nurses and patients according to the International Patient Decision Aid Standards Collaboration criteria. This aid will help improve ...

وصف الملف: application/pdf

العلاقة: Journal of Neuroscience Nursing;55(5); http://dx.doi.org/10.1097/JNN.0000000000000721Test; info:eu-repo/grantAgreement/ES/PERIS/SLT017%2F20%2F000193; Robles-Sanchez MA, Moharra M, Bosch-Farré C, Hernández-Leal MJ, Montalban X, Sastre-Garriga J, et al. Views of Multiple Sclerosis Patients About Key Elements for a Decision Aid: A Qualitative Study. J Neurosci Nurs. 2023 Oct;55(5):164–70.; https://hdl.handle.net/11351/10295Test

الإتاحة: https://doi.org/10.1097/JNN.0000000000000721Test
https://hdl.handle.net/11351/10295Test